#USA #Cambridge #MetaVia #obesity therapies #metabolic therapies

MetaVia's Participation in the Life Sciences Virtual Investor Forum

MetaVia Inc., a biotechnology company based in Cambridge, Massachusetts, has announced its upcoming participation in the Life Sciences Virtual Investor Forum scheduled for June 24, 2026. The event is co-hosted by Zacks Small Cap Research, and the President and CEO, Hyung Heon Kim, will be leading a discussion focused on the company’s innovative pipeline aimed at addressing obesity and other cardiometabolic diseases.

This live, interactive online forum will allow investors to engage directly with company representatives. Attendees will have the opportunity to ask questions in real time, providing a platform for transparency and direct communication regarding MetaVia’s advancements and ambitions. For those unable to attend the live session, an archived webcast will be made accessible post-event, ensuring that information reaches a wider audience.

Investors are encouraged to pre-register and perform an online system check to enhance their participation experience and ensure they receive timely updates related to the event. Additionally, interested investors can schedule one-on-one meetings with MetaVia’s management, which presents a unique chance to delve deeper into the company’s strategies and therapies.

About MetaVia's Therapeutic Developments

MetaVia is at the forefront of innovating treatments for cardiometabolic diseases, specifically with its two promising candidates: DA-1726 and vanoglipel (DA-1241). DA-1726 is designed for treating obesity and operates as a dual agonist, activating both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). This dual action not only curbs food intake but also ramps up energy expenditure, potentially offering superior results in weight loss compared to traditional GLP-1 receptor agonists such as semaglutide. Preliminary Phase 1 clinical trials have shown that DA-1726 holds the promise for exceptional weight reduction, improved glucose control, and a decrease in waist circumference, positioning it as a potential game changer in obesity treatment.

On the other hand, vanoglipel is being developed as a first-in-class drug targeting the G-protein-coupled receptor 119 (GPR119). Its preclinical studies have shown positive outcomes in regulating glucose and lipid levels while offering significant hepatic benefits by reducing liver fat, inflammation, and fibrosis independent of metabolic improvements. A Phase 2a clinical trial highlighted its direct effects on liver health alongside its capabilities in lowering blood sugar levels, showcasing its multi-faceted approach in treating associated metabolic disorders.

Looking Forward: MetaVia’s Vision

As MetaVia prepares for this pivotal investor forum, the focus will not only be on discussing current clinical data but also on painting a broader picture of how these therapies can reshape the landscape of obesity and metabolic disease management. The company’s commitment to innovation and patient care is evident in their ongoing research and development endeavors. As they step onto this platform, MetaVia is poised to capture the attention of investors looking for groundbreaking advancements in biopharmaceutical therapies.

Interested participants and investors wanting to engage more directly with company leadership are advised to take advantage of the meeting opportunities or tune in for insightful discussions that promise to unfold during the forum. To learn more about MetaVia’s promising developments and their impact on the future of metabolic health, visit their official website at metaviatx.com.